Claim-to-reference linking, what it actually checks
How tying a claim to its source works, and why doing it at draft time changes an MLR review.
A promotional claim isn't just a sentence. It's a sentence that has to trace back to something: an approved label, a prescribing information document, or a piece of published clinical evidence. Claim-to-reference linking is the practice of tying each claim to that source at the moment it's written, instead of tracking one down later when a reviewer asks for it.
What it is
Every factual or clinical statement in a promotional asset needs a source that supports it, word for word or close to it. "Reduces symptoms" needs a source that actually says symptoms were reduced, under the conditions the source studied. A claim that's true in spirit but overstates what the source says (a stronger verb, a broader population, a comparison the source never made) is still an unlinked claim in practice, because the reference doesn't back the specific wording used.
The linking itself is usually a citation number or footnote in the finished asset, pointing back to a reference list. What matters is what sits behind that footnote: does the cited source, read plainly, support the exact claim being made, or something adjacent to it.
Why it matters
Claim-to-reference linking is one of the most common places an MLR review sends an asset back for revision, and it's rarely because a claim is fabricated outright. It's almost always a gap between what the source supports and what the copy actually says: a qualifier that got dropped in an edit, a comparison that got sharpened for a headline, a population detail that got generalized for space.
Those small drifts are exactly what a reviewer is trained to catch, and exactly what's expensive to catch late. Finding an unlinked claim during a copy pass costs a rewrite. Finding the same gap during MLR review, after design, legal sign-off, and scheduling are already lined up around the asset, costs a lot more than a rewrite.
How it actually works
A few patterns show up often enough to be worth naming directly:
- Wording drift: the source says "may reduce," the copy says "reduces." Small verb changes are a frequent source of unlinked claims, because they read as harmless in isolation.
- Population drift: a source studied one patient population, and the copy implies it applies more broadly.
- Comparative drift: a source shows a result against placebo, and the copy implies a comparison against a competitor product the source never studied.
- Implied claims: a claim doesn't have to be stated outright to need a reference. A visual showing rapid relief, or a testimonial implying a specific outcome, implies a claim just as much as a headline does.
That last point is why claim-linking has to happen against the actual asset, not just the script or brief that described it. A brief can be fully compliant and still produce a visual that implies something the brief never said.
Common misunderstandings
A common misread is treating claim-linking as a documentation exercise, something done after the copy is final to satisfy a checklist. Treated that way, it catches drift too late to fix cheaply. The other misread is assuming a claim is safe as long as some source somewhere covers the general topic. Linking means the specific wording is supported, not that the general subject has been researched.
Related reading
What is fair balance in pharma promotion?
What fair balance actually requires, why it exists, and where teams most often get it wrong.
The MLR review cycle, step by step, and where it typically stalls
How a promotional asset actually moves through Medical, Legal, and Regulatory review, and the points where it usually gets stuck.